Please login to the form below

Not currently logged in
Email:
Password:

Ardelyx appoints William Bertrand Jr to board of directors

Executive VP of Infinity Pharmaceuticals joins the team
Ardelyx

Ardelyx has appointed William Bertrand Jr to its board of directors.

Ardelyx is a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases.

Bertrand is currently executive VP of general counsel for Infinity Pharmaceuticals and prior to this he served as senior VP and CEO for Salix Pharmaceuticals.

He said: “Ardelyx is uniquely positioned within the life sciences, both in terms of the strength and track record of its senior team, as well as its strategy addressing diseases with substantial unmet needs.”

Mike Raab, president and CEO of Ardelyx, added: “Bill brings extensive experience helping companies growth through early stages of development and into commercialisation.

“His expertise, both operationally and as general counsel, will be of great importance as we continue to accelerate the advancement of our lead programs and develop into a commercial-ready company.”

27th October 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics